DENVER, Oct. 30 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disease, today announced the pricing of its initial public
offering of 5,000,000 shares of its common stock at the public offering price
of $14.00 per share, before underwriting discounts and commissions. The
offering is expected to close November 4, 2003. In addition, Myogen has
granted the underwriters the right to purchase up to an aggregate of an
additional 750,000 shares of common stock to cover over-allotments, if any.
Credit Suisse First Boston and JP Morgan are joint book-running managers for
the offering. CIBC World Markets and Lazard are acting as co-managers.
Copies of the final prospectus related to the offering may be obtained
from Credit Suisse First Boston LLC, Prospectus Department, (One Madison
Avenue, New York, New York 10010 212-325-2580) or J.P. Morgan Securities Inc.
(One Chase Manhattan Plaza, Floor 5B, New York, New York 10081; 212-552-5164).
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on October 29, 2003. The
public offering is being made by means of a prospectus. This press release
shall not constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or
jurisdiction.
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently markets one product
in Europe for the treatment of acute decompensated heart failure and is
developing three product candidates for three distinct cardiovascular
indications. The Company also conducts a target and drug discovery research
program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com .
This press release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed in this release
and others that can be found in the "Risk Factors" section of Myogen's
Registration Statement on Form S-1 on file with the SEC. Myogen is providing
this information as of this date and does not undertake any obligation to
update any forward-looking statements contained in this document as a result
of new information, future events or otherwise. Prior to this offering there
has not been a public market for Myogen's common stock. There can be no
assurance that an active trading market for the common stock will develop
following this offering. The market price of Myogen's common stock may be
highly volatile. No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. The Company is at an
early stage of development and may not ever have any products that generate
significant revenue.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations,
+1-303-464-3986, derek.cole@myogen.com , or Joseph L. Turner,
Chief Financial Officer, +1-303-464-5222, joe.turner@myogen.com ,
both of Myogen, Inc.
|
